# AstraZeneca’s Fasenra phase III OSTRO trial met co-primary endpoints

- Link: https://www.directorstalkinterviews.com/astrazenecas-fasenra-phase-iii-ostro-trial-met-co-primary-endpoints/412857577
- Published: 2020-09-10T07:41:03+01:00
- Author: Amilia Stone

High-level results from the OSTRO Phase III trial showed **[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Fasenra_ (benralizumab) compared with placebo demonstrated a statistically significant
improvement in the size of nasal polyps and in nasal blockage in patients with chronic
rhinosinusitis with nasal polyps (CRSwNP).

_Fasenra_ demonstrated a statistically significant improvement in the endoscopic
total nasal polyp score (NPS) and the nasal blockage score (NBS) compared to placebo,
in patients with severe bilateral nasal polyposis who were still symptomatic despite
continued treatment with standard of care (SoC). SoC consists of intranasal corticosteroids(
INCS) and prior surgery and/or use of systemic corticosteroids. Evaluation of NPS
was based on a physician assessment of polyp size during endoscopy. NBS evaluation
was based on a patient-reported symptoms diary.

CRSwNP is an inflammatory disease associated with elevated levels of eosinophils
in the upper respiratory tract and characterised by benign growths called nasal 
polyps.^(1,2) Polyps can cause nasal blockage and discharge, reduction or loss in
the sense of smell, sleep disturbances and other adverse effects on quality of life.
^(3-5)

> **Professor Claus Bachert, Head of the Department of Oto-Rhino-Laryngology and
> Chair of the Upper Airway Research Laboratory, University Hospital Ghent, Belgium,
> the principal investigator of the trial, said: **“Chronic rhinosinusitis with 
> nasal polyps is difficult to treat and the underlying drivers and natural history
> of the disease are not fully established. The OSTRO results show that _Fasenra’s_
> eosinophil-depleting mechanism of action may benefit patients with this often 
> debilitating condition.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said:** “Patients
> with chronic rhinosinusitis with nasal polyps suffer significantly with nasal 
> congestion and a reduced quality of life. Current treatments, such as intranasal
> or oral corticosteroids and surgery to remove polyps, do not fully address patient
> needs. The OSTRO data indicate _Fasenra_ can benefit patients with nasal polyps.
> We look forward to completing the full analysis and sharing these results at an
> upcoming medical meeting.”

The safety profile and tolerability of _Fasenra_ in this trial were consistent with
the known profile of the medicine.

_Fasenra_ is currently approved as an add-on maintenance treatment for severe eosinophilic
asthma in the US, EU, Japan and other countries and is approved for self-administration
in the US, EU and other countries.

**Chronic rhinosinusitis with nasal polyps**

Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterised by persistent
inflammation of the mucous membrane lining the nasal passages and sinuses accompanied
by benign growths, called nasal polyps.^(6,7) Nasal polyps can block nasal passages
and lead to breathing problems, reduction in the sense of smell, nasal discharge,
sleep disturbance and other adverse effects on quality of life.^(3-5) The disease
is associated with elevated levels of eosinophils, a type of white blood cell, accumulating
in the upper respiratory tract.^(2)

Current treatments for nasal polyps include intranasal or oral corticosteroids (
OCS) and surgery to remove polyps, but these often do not address the underlying
cause of the disease and the need for repeated interventions can be high. Since 
2019, other biologic medicines have been approved or recommended to treat nasal 
polyps.^(4,10)

OSTRO is part of AstraZeneca’s clinical trial programme for _Fasenra_ in CRSwNP 
which also includes the ongoing Phase III ORCHID trial, among others.^(11)

**OSTRO**

OSTRO is a randomised, double-blinded, multi-centre, parallel-group, 56-week Phase
III trial to evaluate the efficacy and safety of _Fasenra_ compared to placebo in
patients with nasal polyposis.^(12) _Fasenra_ was evaluated in patients, regardless
of blood eosinophil count with or without asthma, who were symptomatic despite SoC
therapy, including current use of INCS and prior surgery and/or use of systemic 
corticosteroids. Patients were randomised to receive either _Fasenra_ 30mg or placebo
subcutaneously every four weeks for the first three doses and every eight weeks 
thereafter.^(12)

The primary outcome measures of the trial were: the effect of _Fasenra_ on nasal
polyp burden, assessed by change from baseline in endoscopic total NPS, at week 
40 compared to placebo; the effect of _Fasenra_ on patient-reported nasal blockage,
assessed by change from baseline in mean NBS, at week 40 compared to placebo. OSTRO
involved 413 patients in Europe and North America.^(12)

**Fasenra**

_Fasenra_ (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor
alpha on eosinophils and attracts natural killer cells to induce rapid and near-
complete depletion of eosinophils via apoptosis (programmed cell death).^(13,14)

_Fasenra_ is in development for other eosinophilic diseases and chronic obstructive
pulmonary disease.^(15-19) The US Food and Drug Administration granted Orphan Drug
Designation for _Fasenra_ for the treatment of eosinophilic granulomatosis with 
polyangiitis in 2018, and hypereosinophilic syndrome and eosinophilic oesophagitis
in 2019.

_Fasenra_ was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-
owned subsidiary of Kyowa Kirin Co., Ltd., Japan.

Share on:
